Nanosonics Receives FDA De Novo Clearance for CORIS
Filed with ASX · · 1 page · English
Summary by 6ix AI
Nanosonics Limited announces that it has received FDA De Novo clearance for its CORIS system, which is designed to enhance cleaning outcomes for flexible endoscopes and reduce infection risks. The CORIS system aims to automate cleaning processes, addressing significant challenges in medical device reprocessing. The initial phase of commercialization is set to focus on market awareness and controlled releases in hospitals before broader distribution.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Nanosonics
- 2025 Half Year Financial Results
- Appendix 4D and Half Year Accounts
- H1 FY25 trading update
- Response to ASX Query
- S&P DJI Announces September 2024 Quarterly Rebalance
Later from Nanosonics
- Response to ASX Price Query
- Nanosonics launches trophon3 and trophon2 Plus software
- US FDA clearance received for next generation trophon
- Appendix 4E
- Nanosonics to commence $20 million share buy-back program
Follow Nanosonics into a list and get an email when it puts out news.
Follow Nanosonics